Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following ...
Citius Pharmaceuticals Inc (NASDAQ:CTXR) is a small-cap stock with a market capitalization of USD $26.49M. While investors primarily focus on the growth potential and competitive landscape of the ...
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) shares jumped 22.12% in after-hours trading to $1.27 on Tuesday, following the company’s fiscal year 2025 business update and the commercial launch of its ...
Fintel reports that on December 30, 2024, D. Boral Capital upgraded their outlook for Citius Pharmaceuticals (NasdaqCM:CTXR) from Hold to Buy. As of December 23, 2024, the average one-year price ...
Citius Pharmaceuticals, Inc. CTXR announced top-line data from the pivotal phase III study evaluating its novel IL-2R immunotherapy, I/ONTAK (E7777), for the treatment of patients with persistent or ...
CTXR is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of CTXR shares has increased $0.03 since the market last closed. This is a 4.48% ...
Citius Pharmaceuticals Inc. Annual cash flow by MarketWatch. View CTXR net cash flow, operating cash flow, operating expenses and cash dividends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results